Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 11;6(1):e128.
doi: 10.1097/j.pbj.0000000000000128. eCollection 2021 Jan-Feb.

What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review

Henrique Castro Santos  1 , João Gama Marques  1   2
Affiliations
Review

What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review

Henrique Castro Santos et al. Porto Biomed J. .

Abstract

Background: Psilocybin is a predominant agonist of 5HT1A and 5HT2A/C receptors and was first isolated in 1958, shortly before it became a controlled substance. Research on the potential therapeutic effects of this compound has recently re-emerged alongside what is being addressed as a psychedelic renaissance.

Methods: In this paper we performed a systematic review of the clinical trials conducted so far regarding the therapeutic effects of psilocybin on psychiatric disorders. The eligibility criteria included clinical trials that assessed psilocybin's potential therapeutic effects on patients with psychiatric disorders. Nine hundred seven articles were found and screened in regard to the title, from which 94 were screened through abstract and 9 met the eligibility criteria and were included.

Results: The papers published focused on 3 disorders: depression, obsessive-compulsive disorder (OCD) and substance use disorder (namely tobacco and alcohol). Psilocybin has shown a relatively safe profile and very promising results, with reductions found on most of the psychiatric rating scales' scores. Research on depression showed the most solid evidence, supported by 3 randomized controlled trials. Studies on OCD and substance use disorder showed more limitations due to their open-label design.

Conclusions: Altogether, the results from the studies reviewed in this paper suggest a substantial therapeutic potential. This calls for further research to confirm the results observed so far and further explain the underlying mechanisms.

Keywords: anxiety; depression; obsessive-compulsive disorder; psilocybin; substance-related disorders.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Flow of citations according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Passie T, Seifert J, Schneider U, Emrich HM. The pharmacology of psilocybin. Addict Biol. 2002;7:357–364. - PubMed
    1. Tylš F, Páleníček T, Horáček J. Psilocybin—summary of knowledge and new perspectives. Eur Neuropsychopharmacol. 2014;24:342–356. - PubMed
    1. Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. Acute psychological and physiological affects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology. 2004;172:145–156. - PubMed
    1. Nichols DE. Hallucinogens. Pharmacol Ther. 2004;101:131–181. - PubMed
    1. Stamets P. Psilocybin Mushrooms of the World: An Identification Guide [Internet]. Ten Speed Press; 1996: 258 p. Available from: http://books.google.com/books?id=GAmfNNwHkjIC. Accessed November 2018.

LinkOut - more resources